Back to Search
Start Over
A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS
- Source :
- Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p5067-5067, 1p
- Publication Year :
- 2017
-
Abstract
- Hypomethylating agents are standard first line therapy for older patients with AML and MDS. While these agents can prolong overall survival and disease free survival, they are not curative and only result in a complete response in about 20-25% of patients. For patients that fail these agents, there are no standard treatment options and overall survival is short at 4-6 months.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 130
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56863973
- Full Text :
- https://doi.org/10.1182/blood.V130.Suppl_1.5067.5067